WHO Adds Rare Disease Treatments to the Essential Medicines List
Salome Mekhuzla, Director of Global Development at the World Federation of Hemophilia, reposted from Rare Diseases International on LinkedIn:
”Thrilled to have contributed to this project and congratulations to RDI team on all the work accomplished.”
Quoting Rare Diseases International‘s post:
”New Report Published!
With the publication of the updated WHO Model List of Essential Medicines (EML) and the Model List for Children (EMLc), important progress has been made: for the first time, treatments for several rare diseases have been included. This achievement highlights how advocacy and active engagement are vital to ensure that more therapies for rare diseases are recognized as essential in the future. In this context, RDI is proud to share the publication of the Essential Medicines Working Group (EMWG) Report.
This report, developed by RDI’s Essential Medicines Working Group, explores:
- Successful and unsuccessful applications for rare disease medicines to the EML, identifying challenges, success factors, and opportunities to strengthen the evaluation process for essential RD medicines.
- Concrete recommendations and a Call-to-Action to strengthen the EML’s impact for people living with rare diseases globally.
This work would not have been possible without the invaluable contributions of the members of the RDI Essential Medicines Working Group and the organizations that generously shared their experiences. Special thanks to all contributors for their dedication and insights. This project was developed by RDI Global Programme: Chiuhui Mary Wang, Chiara Tovani and Sara Brambilla.
Read the full report here․
For more information, check our website․”
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM
-
Aug 26, 2026, 13:59David McIntosh: Immunoglobulin Stewardship in the Face of Rising Demand